-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 20, Kang Enbei issued an announcement stating that its wholly-owned subsidiary Hangzhou Kang Enbei received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration, and pioglitazone hydrochloride tablets passed the consistency evaluation of generic drugs
Pioglitazone hydrochloride tablets are mainly used to treat type 2 diabetes
As of the disclosure date of this announcement, three manufacturers of pioglitazone hydrochloride tablets that have passed the consistency evaluation include Hangzhou Kangenbei, a wholly-owned subsidiary of the company
Meinenet data shows that in 2020, the sales of pioglitazone hydrochloride oral preparations in public medical institutions and retail pharmacies are 774 million yuan and 123 million yuan, respectively.
Up to now, Hangzhou Conba has invested approximately RMB 10.
According to relevant national policies, medicines that pass the consistency evaluation will receive greater support in areas such as medical insurance payment and procurement by medical institutions